Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07124351 · ClinicalTrials.gov registry record · Phase 4
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
A Phase 4 study of Gastric Cancer and Esophageal Cancer, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07124351: Recruiting Phase 4 study of Gastric Cancer and Esophageal Cancer, sponsored by Cedars-Sinai Medical Center.
NCT07124351 is a Phase 4 study of Gastric Cancer and Esophageal Cancer that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 15 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07124351, a Phase 4 study of Gastric Cancer and Esophageal Cancer, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).
Primary Outcome
Determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal) in at least 70% of the patients.
Conditions Studied
Interventions
- DRUG CYTALUX™ (pafolacianine)
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
What NCT07124351 shows while recruiting
NCT07124351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which CYTALUX™ (pafolacianine) is the first listed.
NCT07124351 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07124351 about?
NCT07124351 is a clinical study titled "Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)". This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).
What is the current status of trial NCT07124351?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2025-09-05. Estimated completion is 2026-09.
What conditions does trial NCT07124351 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, Gastrointestinal Cancer, Appendiceal Cancer.
What interventions are being tested in trial NCT07124351?
The interventions under investigation include: CYTALUX™ (pafolacianine) (DRUG).
Who is sponsoring clinical trial NCT07124351?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07124351 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07124351's enrollment target sits among peer trials
15 149th of 153 higher than 4 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
ACTIVE NOT RECRUITING · Phase 4
-
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
ACTIVE NOT RECRUITING · Phase 4
-
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
COMPLETED · Phase 4
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI